On March 8, 2022 Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, reported dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients with advanced cancers (Press release, Palleon Pharmaceuticals, MAR 8, 2022, View Source [SID1234609700]). The study, called GLIMMER-01 (Glycan-Mediated Immune Regulation), is the first clinical study of Palleon’s novel approach to cancer immunotherapy which targets immunosuppressive sialoglycans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

E-602 is Palleon’s lead program in oncology and the first candidate generated from the company’s EAGLE platform. E-602 is composed of two engineered human sialidase molecules fused to a human monoclonal antibody. Preclinical studies have demonstrated that E-602 degrades terminal sialic acids on immunosuppressive sialoglycans on both tumor cells and immune cells, restoring both innate and adaptive antitumor immunity.

"We’re very excited to bring our first therapeutic candidate into the clinic. This milestone is significant not just for Palleon, but for the broader immuno-oncology community, as we test a bold new approach to releasing immune suppression by modifying cancer cell-surface glycans," said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. "We continue to pursue research at the forefront of glyco-immunology to advance other novel therapies for cancer and inflammatory diseases into the clinic and ultimately to patients."

The GLIMMER-01 trial (NCT05259696) is an open-label, dose-escalation, and dose-expansion study. It will evaluate safety, pharmacodynamic effects, and antitumor activity of E-602, both as a single agent and in combination with pembrolizumab (anti-PD-1). The study will enroll patients with previously treated non-small cell lung cancer, colorectal cancer, melanoma, pancreatic cancer, and ovarian cancer.

"First generation immune checkpoint inhibitors demonstrated remarkable efficacy for patients with many types of cancer. However, only a minority of patients benefit from these therapies," said David Feltquate, M.D., Ph.D., Chief Medical Officer of Palleon. "Novel approaches to overcoming immune resistance are needed. Today marks an important milestone for the nascent field of glyco-immunology as we explore the potential of altering the immune suppressing effects of inhibitory sialoglycans."

On March 8, 2022 Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, reported that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will present at Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-17, 2022 (Press release, Ambrx, MAR 8, 2022, View Source [SID1234609699]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tian is scheduled to present on Thursday, March 17, at 12:40 p.m. Eastern Time.

Interested parties can access the live webcast for this conference from the Investor Relations section of the company’s website at www.ambrx.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 90 days.

On March 8, 2022 NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, reported that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will participate in an upcoming corporate event hosted by Oppenheimer & Co. Inc (Press release, NorthStar Medical Radiostopes, MAR 8, 2022, View Source [SID1234609698]). The fireside chat, "Radiopharmaceutical Therapies Come of Age," will be held in virtual format on Monday, March 14, 2022, at 1:00 p.m. ET. Topics of discussion will include: development strategy for targeted radiotherapy using alpha and beta-emitting radioisotopes; supply, manufacturing and transportation challenges; and strategies for limiting systemic toxicities. Additional information is available here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NorthStar continues to expand our leadership position in the rapidly growing area of therapeutic radioisotopes, which are used in targeted precision radiopharmaceuticals for the treatment of cancer, respiratory and other diseases," said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes. "NorthStar is poised to be the first commercial-scale producer of therapeutic radioisotopes copper-67 and actinium-225, and strongly positioned for continued rapid growth. We look forward to sharing information about our innovative and environmentally sustainable approach to radioisotope production with the investor community at this Oppenheimer fireside chat."

On March 8, 2022 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, reported that its Board of Directors has authorized a share repurchase program under which Fulgent may repurchase up to $250 million in shares of its common stock (Press release, Fulgent Pharma, MAR 8, 2022, View Source [SID1234609697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Given the volatility we have seen in our share price, we believe current trading levels present an attractive opportunity to implement a share repurchase program as a way to return capital to our shareholders," said Paul Kim, Chief Financial Officer of Fulgent. "With our current cash, cash equivalents and investments in marketable securities position now exceeding $1.0 billion, we believe we remain extremely well capitalized to make strategic investments to drive growth as we implement this share repurchase program."

The timing and amount of any shares repurchased will be determined by Fulgent’s management based on its evaluation of market conditions and other factors. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The repurchase program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with its stock plans and for other corporate purposes.

The repurchase program will be funded using Fulgent’s working capital. Fulgent had approximately 30.3 million shares of common stock outstanding as of March 7, 2022.

On March 8, 2022 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") , a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, reported that members of its management team are scheduled to virtually participate in Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 (Press release, Fulgent Pharma, MAR 8, 2022, View Source [SID1234609696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These representatives of the company will conduct a presentation beginning at approximately 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at ir.fulgentgenetics.com beginning approximately one hour following the completion of the event.